Investigating the effect of ketamine on psychosomatic pai

Phase 3

• Conditions: somatic symptoms disorder with pain predominance.; Persistent somatoform pain disorder; p45.4

• Registration Number: IRCT20090801002266N20
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 24 June 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 84

Inclusion Criteria

Diagnosis of somatic symptom disorder with obvious pain complaint based on DSM-V criteria
Informed consent to participate in the study
Age group 18-60 years
No history of mania/hypomania
No presence of symptoms of psychosis in the patient's current or past history
No history of drug dependence or abuse in the last 3 months
No Pregnancy or lactation
No Serious and uncontroled physical patients, including liver, kidney, digestive, respiratory, cardiovascular (such as ischemic heart diseases), endocrine, neurological, increased intraocular pressure or increased cerebrospinal fluid pressure, hematological (on Based on the history of the patient and companions, and if needed, paraclinical examination and consultation)
No taking any kind of medicine that is prohibited to use at the same time as ketamine
Untreated hypothyroidism or hyperthyroidism. (due to the instability of physical and vital signs)

Exclusion Criteria

Emergence of psychosis and psychotic symptoms
Patients who became out of reach of the researcher in the follow-up process
Annoying and uncontrollable side effects with ketamine use

Study & Design

• Study Type: interventional
• Study Design: Not specified